Dr. Benjamin R. Puliafito, MD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- Albert Einstein College of Medicine of Yeshiva University (2018)
- Years since graduation
- 8
- In the NPI registry since
- 2018
- Medicare patients seen, 2024
- 37
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2018Medical school: Albert Einstein College of Medicine of Yeshiva University
- 2018Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
MA license 1019384 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- Newton-Wellesley Hospital Newton, MA
- North Shore Medical Center - Salem, MA
- Massachusetts Eye and Ear Infirmary - Boston, MA
Medical groups
- Massachusetts General Physicians Organization Inc (3,558 clinicians)
- The General Hospital Corporation (1,267 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 37
- Services billed
- 104
- Patients’ average age
- 75
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Boston, MA | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 11 payments worth $2,855 in total to this clinician.
| Legend Biotech USA Inc. | $2,338 |
|---|---|
| Genzyme Corporation | $183 |
| Kite Pharma, Inc. | $145 |
| Stryker Corporation | $130 |
| AstraZeneca Pharmaceuticals LP | $60.00 |
| Consulting Fee | $2,145 |
|---|---|
| Food and Beverage | $710 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Legend Biotech USA Inc. Dec 18, 2025 | Consulting Fee CARVYKTI · Oncology | $2,145 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $119,100 in research payments for these studies, mostly to the institutions running them.
- A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.